8月12日 - ** 制药公司Neurocrine Biosciences（NBIX.O）的股价在盘前交易中下跌4.9%，至154美元
** 周二，三家机构发布联合声明（(link)），援引上市后报告称，在接受NBIX公司药物Vykat XR治疗的患者中，已发生7例死亡病例及超过100例严重不良事件报告，该药物于2025年3月获批
** 该药物用于治疗贪食症，这是普拉德-威利综合征（Prader-Willi syndrome）的标志性症状。该遗传性疾病由第15号染色体的全部或部分缺失引起，这些缺失会影响基因表达的调控，即基因的开启与关闭机制
** 不过，相关机构强调，这些报告并未确立Vykat XR与不良结果之间的因果关系
**今年早些时候，Neurocrine通过以29亿美元收购Soleno Therapeutics（(link)），将Vykat XR纳入其产品组合
** 美国食品药品监督管理局（FDA）数据库显示，有4例死亡病例与该药物相关
** Neurocrine公司和美国FDA尚未立即回应路透的置评请求
** 截至上一交易日收盘，该股年内累计上涨14.2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.